ClinicalTrials.gg
CompletedNCT04805606Updated Apr 6, 2022

A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843

A Phase 1 interventional study of CKD-843 A and CKD-843 B in Alopecia, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Alopecia with a site in Korea, Republic of — 5 open to participants now, 5 under way, 3 of them phase 3. Alopecia · Korea, Republic of.

Enrollment
15th of 21
40 · median 80
Started
2021
with 1 other
Phase 1
4 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
4 of 22
Chong Kun Dang Pharmaceutical

Among the 22 studies in Alopecia with a site in Korea, Republic of, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 1, and was the 13th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

5 of the 22 studies in Alopecia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 19 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Alopecia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843

Read the detailed description

A Randomized, Open-label, and Parallel Study to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843 in Male Volunteers

03

Conditions studied

  • Alopecia

Browse trials for

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Those who aged between 19 to 50 inclusion of man who concerned about androgenic alopecia.
  • Those who has body weight ≥ 50kg.
  • Those who has calculated (BMI) of 18.5 ≤ \~ \< 27.0 kg/m2

    • Body Mass Index, kg/m2= Body weight(kg)/[Height(m)2]
  • Those who consent to proper and do not donate sperm until 6 months after the last administration of product.
  • Those who understanding the detailed description of this clinical trial and voluntarily decide to participate.

Exclusion criteria

Exclusion Criteria:

  • Those who have disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Hemato-oncology disorder, Cardiovascular disorder or Psychical disorder
  • Those who have history of to active pharmaceutical ingredient, 5α-reductase inhibitor, tocopherol.
  • Those who have the screening(D-28\~D-2) test results written below

    • , ALT > 1.25 times higher than upper normal level
    • Total > 1.5 times higher than upper normal level
    • (estimated Glomerular Filtration Rate, which is calculated by MDRD) \< 60 mL/min/1.73m2
    • "Positive" or "Reactive" test result of \& C, , RPR
    • Under 5 min resting condition, systolic blood pressure >150 mmHg or \<90 mmHg, diastolic blood pressure >100 mmHg or \<50 mmHg
  • Those who have a drug abuse history within one year or positive reaction on urine drug screening test.
  • Those who received following drugs, which may affect results of clinical trial and safety Ethical-the-counter (ETC) drugs and herbal medicines within 14 days before the first administration and Over-the-counter (OTC) drugs, health foods and vitamin preparations within 7 days before the first administration of the product.
  • Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 30 days before the first administration of investigational product.
  • Those who exceeding smoke consumption criteria or can't stop smoking during hospitalization period.

    • Criteria: Smoke > 10 cigarettes/day
  • Those who exceeding an alcohol and caffeine consumption criteria or can't stop consuming alcohol and caffeine during hospitalization period.

    • Criteria: Caffeine > 5 cups/day, Alcohol > 210 g/week
  • Those who took grapefruit within 7 days before the first administration of investigational product.
  • Those who received investigational product by participating in other clinical trial within 6 months before the first administration of investigational product.
  • Those who donated whole blood within 60 days or apheresis within 30 days before the first administration of investigational product.
  • Those who received transfusion within 30 days before the first administration of investigational product.
  • Those who are deemed inappropriate to participate in clinical trial by investigators.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Sequence 1

    CKD-843 A - 27mg, Single Dose

    Drug: CKD-843 A

  • Experimental
    Sequence 2

    CKD-843 A - 45mg, Single Dose

    Drug: CKD-843 A

  • Experimental
    Sequence 3

    CKD-843 A - 56mg, Single Dose

    Drug: CKD-843 A

  • Experimental
    Sequence 4

    CKD-843 B - 45mg, Single Dose

    Drug: CKD-843 B

  • Active comparator
    Sequence 5

    CKD-843-R

    Drug: CKD-843-R

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast of CKD-843 A, CKD-843 B

    Area under the concentration-time curve from time zero to last

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  2. AUCinf of CKD-843 A, CKD-843 B

    Area under the concentration-time curve from zero up to ∞

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  3. AUC0-90days of CKD-843 A, CKD-843 B

    Area under the concentration-time curve from time zero to 90 days

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  4. AUClast of CKD-843-R

    Area under the concentration-time curve from time zero to last

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

  5. AUCinf of CKD-843-R

    Area under the concentration-time curve from zero up to ∞

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

  6. AUC0-90days of CKD-843-R

    Area under the concentration-time curve from time zero to 90 days

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

Secondary outcomes

  1. Tmax of CKD-843 A, CKD-843 B

    Time to maximum plasma concentration

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  2. t1/2 of CKD-843 A, CKD-843 B

    Terminal elimination half-life

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  3. CL/F of CKD-843 A, CKD-843 B

    Apparent clearance

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  4. Vd/F of CKD-843 A, CKD-843 B

    Apparent volume of distribution

    Time frame: Day 1(Pre-dose(0 hour), 2, 4, 8 12 hours)

  5. Tmax of CKD-843-R

    Time to maximum plasma concentration

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

  6. t1/2 of CKD-843-R

    Terminal elimination half-life

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

  7. CL/F of CKD-843-R

    Apparent clearance

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

  8. Vd/F of CKD-843-R

    Apparent volume of distribution

    Time frame: Day 1(Pre-dose(0 hour), 1, 2, 3, 4, 6, 8, 10, 12 hours)

07

Study locations

1 site
  • Severance Hospital
    Seoul, 120-752, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2021, 7 months.

Of 33 phase 1 interventional studies under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Mar 18, 2021
StartActual
Apr 30, 2021
Primary completionActual
Dec 24, 2021
CompletionActual
Dec 24, 2021
Last update
Apr 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04805606
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Apr 30, 2021
Primary completion
Dec 24, 2021
Completion
Dec 24, 2021
Last update
Apr 6, 2022

Study contacts

MinSoo Park, M.D. Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CKD-843

Start the discussion